A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie zaawansowanego raka płuc (małokomórkowego), który wrócił lub nie reaguje na leczenie
- •Wcześniejsze leczenie chemioterapią opartą na platynie i innymi zatwierdzonymi lekami
- •Ogólny stan zdrowia pozwalający na otrzymanie porównywanych leków
- •Możliwość zmierzenia zmian nowotworu podczas badań obrazowych
- •Stan zdrowia oceniony jako dobry (skala ECOG 0-1)
- •Jeśli są przerzuty do mózgu - wcześniej leczone i stabilne lub niewielkie i bez objawów
✗ Disqualifies
- •Aktywne i powodujące objawy przerzuty do mózgu wymagające dodatkowego leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (72)
Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063
Birmingham, United States
Usa Mitchell Cancer Institute /ID# 280198
Mobile, United States
City Of Hope - Phoenix /ID# 281323
Goodyear, United States
City of Hope National Medical Center /ID# 281322
Duarte, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396
Irvine, United States
Florida Cancer Specialists & Research Institute - South /ID# 281387
Fort Myers, United States
Orlando Health Cancer Institute /ID# 280418
Orlando, United States
Moffitt Cancer Center /ID# 279732
Tampa, United States
City Of Hope - Atlanta /ID# 279929
Newnan, United States
University of Chicago Medical Center /ID# 280149
Chicago, United States
OSF St. Francis Medical Center /ID# 279930
Peoria, United States
Springfield Clinic - First /ID# 281309
Springfield, United States
City Of Hope - Chicago /ID# 281335
Zion, United States
Franciscan St. Francis Health /ID# 279788
Indianapolis, United States
Baptist Health Louisville /ID# 280025
Louisville, United States
Dana-Farber Cancer Institute /ID# 279690
Boston, United States
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955
Grand Rapids, United States
Minnesota Oncology - Edina Clinic /ID# 280698
Edina, United States
Mayo Clinic Hospital Rochester /ID# 279784
Rochester, United States
Inspira Medical Center Mullica Hill /ID# 280574
Mullica Hill, United States
FirstHealth of the Carolinas- Speciality Center /ID# 279857
Pinehurst, United States
Oncology Hematology Care - Fairfield /ID# 280641
Fairfield, United States
Willamette Valley Cancer Institute and Research Center /ID# 280617
Eugene, United States
Oregon Health and Science University /ID# 280071
Portland, United States
St. Lukes University Hospital /ID# 280204
Bethlehem, United States
Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619
Knoxville, United States
University Of Tennessee Medical Center /ID# 279896
Knoxville, United States
Baptist Memorial Hospital /ID# 281405
Memphis, United States
SCRI Oncology Partners /ID# 279779
Nashville, United States
Vanderbilt University Medical Center /ID# 280169
Nashville, United States
The University of Texas MD Anderson Cancer Center /ID# 280070
Houston, United States
Texas Oncology - Northeast Texas /ID# 280642
Tyler, United States
Blue Ridge Cancer Care - Blacksburg /ID# 281583
Blacksburg, United States
Virginia Cancer Specialists - Fairfax /ID# 280710
Fairfax, United States
Shenandoah Oncology /ID# 280699
Winchester, United States
West Virginia University Hospitals /ID# 279883
Morgantown, United States
University of Wisconsin /ID# 279909
Madison, United States
Universitaetsklinikum Krems /ID# 280608
Krems, Austria
Ordensklinikum Linz Elisabethinen /ID# 281314
Linz, Austria
AZ-Delta. /ID# 280341
Roeselare, Belgium
Hospital Sirio Libanes - Sao Paulo /ID# 279948
São Paulo, Brazil
Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 280600
Marseille, France
Universtaetsklinikum Wuerzburg /ID# 280834
Würzburg, Germany
Klinikum Kassel /ID# 280427
Kassel, Germany
Universitaetsklinikum Koeln /ID# 280867
Cologne, Germany
Klinikum Koeln-Merheim /ID# 280958
Cologne, Germany
Henry Dunnant Hospital Center /ID# 280369
Athens, Greece
Metropolitan Hospital /ID# 280359
Piraeus, Greece
Interbalkan Medical Center Of Thessaloniki /ID# 280361
Thessaloniki, Greece
Fujita Health University Hospital /ID# 279969
Toyoake, Japan
Hirosaki University Hospital /ID# 279926
Hirosaki, Japan
Kyushu University Hospital /ID# 279964
Fukuoka, Japan
Hokkaido Cancer Center /ID# 280024
Sapporo, Japan
Kobe University Hospital /ID# 280290
Kobe, Japan
Kitasato University Hospital /ID# 280033
Sagamihara-shi, Japan
Sendai Kousei Hospital /ID# 279790
Sendai, Japan
Niigata University Medical and Dental Hospital /ID# 280027
Niigata, Japan
Okayama University Hospital /ID# 280023
Okayama, Japan
Kansai Medical University Hospital /ID# 279925
Hirakata-shi, Japan
Osaka International Cancer Institute /ID# 280026
Osaka, Japan
Kindai University Hospital /ID# 280034
Sakai-shi, Japan
Saitama Medical University International Medical Center /ID# 279962
Hidaka, Japan
Shizuoka Cancer Center /ID# 279924
Sunto-gun, Japan
Juntendo University Hospital /ID# 280095
Bunkyo-ku, Japan
Nippon Medical School Hospital /ID# 280687
Bunkyo-ku, Japan
Teikyo University Hospital /ID# 280307
Tokyo, Japan
Hospital Clinic de Barcelona /ID# 281271
Barcelona, Spain
Hospital Universitario Ramon y Cajal /ID# 280888
Madrid, Spain
University Hospital Basel /ID# 280787
Basel Town, Switzerland
Hopitaux Universitaires de Geneve /ID# 280748
Geneva, Switzerland
Centre Hospitalier Universitaire Vaudois /ID# 280847
Lausanne, Switzerland
EOC Ospedale Regionale Lugano /ID# 280583
Lugano, Switzerland
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.